Today (April 8), PDRN raw material supplier Ruijiming (Shandong) Biotechnology Co., Ltd. (hereinafter referred to as “Ruijiming Bio”) officially announced that it has recently completed a new round of financing worth tens of millions of RMB. The funds will provide strong support for its subsequent R&D innovation, capacity expansion, market development, and industrial development.
According to public information, Ruijiming Bio was established in August 2020. It is an innovative company focused on raw materials for marine bio-regenerative medicine and aesthetics. The company specializes in the R&D, production, and sales of pharmaceutical products, medical aesthetics, and cosmetic ingredients, and has independently developed PDRN, PN raw materials, as well as multiple new bio-nucleic acid-based ingredients.
It is reported that PDRN, whose scientific name is polydeoxyribonucleotide, was initially extracted from salmon tissue. Due to its base composition being up to 98% similar to human DNA, it offers high biocompatibility and absorption efficiency. Studies have shown that PDRN delivers multiple benefits, including promoting cell repair, anti-inflammation, and anti-aging, and has been widely used in the cosmetics field in recent years.
“Since its establishment, the company has adhered to technological innovation as its core, focusing on the fields of marine bio-regenerative medicine and synthetic biology. It has broken through international technological monopolies and achieved the localized, large-scale production of pharmaceutical-grade PDRN/PN raw materials,” said Dong Shuping, Chairman of Ruijiming Bio. In the future, the company will continue to increase R&D investment, accelerate the commercialization of biomedical products, and provide higher-quality and more competitive raw material solutions for the field of regenerative medical aesthetics.
To date, Ruijiming Bio has completed three rounds of financing. Its Series A round was led by Huixi Industrial Investment Life Science Venture Capital (Huzhou) Partnership, with participation from Shanghai Shuiyang Management Consulting Co., Ltd. The former is an industrial investment fund focused on life sciences and the broader health sector, in which Bloomage Biotech holds a 29.99% stake as the second-largest partner; the latter is a wholly owned subsidiary of Shuiyang Group Co., Ltd.
